Allyson Pishko/pennmedicine.org
Aug 14, 2025, 12:52
JAMA Review: Immune Thrombotic Thrombocytopenic Purpura (iTTP)
JAMA shared an insightful post on X:
“Immune thrombotic thrombocytopenic purpura (iTTP) is a rare immune-mediated disorder characterized by thrombocytopenia and microangiopathic hemolytic anemia, potentially causing life-threatening thrombosis.”
Read the full review here.
Article: Immune Thrombotic Thrombocytopenic Purpura
Authors: Allyson M. Pishko, Ang Li, Adam Cuker
Stay informed on all science in the field of platelet disorders with Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial